Table 1.

Demographic and disease characteristics of early- and delayed treatment patients participating in the BENEFITstudy.

	Early treatment (n = 292)	Delayed treatment (n = 176)
Women, n (%)	207 (70.9)	124 (70.5)
Age, years, mean (median)	30.8 (30.0)	30.7 (30.0)
EDSS at screening, mean (median)	1.9 (2.0)	1.8 (2.0)
EDSS at baseline, mean (median)	1.6 (1.5)	1.5 (1.5)
PASAT-3” score at screening, mean (median)	46.5 (49.0)	46.2 (48.5)
PASAT-3” score at baseline, mean (median)	52.4 (55.0)	52.8 (55.0)
Patients with >9 T2 lesions at baseline, n (%)	207 (70.9)	123 (69.9)
Patients with ≥1 gadolinium-enhancing lesion at baseline, n (%)	127 (43.5)	70 (39.9)

EDSS, Expanded Disability Status Scale; PASAT-3”, Paced Auditory Serial Addition Test-3”